817 results on '"Shain, Kenneth"'
Search Results
52. Supplementary Figure Legend from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
53. Supplementary Figure 2 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
54. Data from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
55. Supplementary Figure 7 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
56. Supplementary Figure 3 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
57. Supplementary Figures 1-14 from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
58. Supplementary Figure 1 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
59. Supplementary Figure 6 from A Preclinical Assay for Chemosensitivity in Multiple Myeloma
60. Supplementary Methods and Materials from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
61. Hematopoietic Recovery after Anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T Cell Therapy (CAR T), Idecabtagene Vicleucel (Ide-cel), for Relapsed/ Refractory Multiple Myeloma (RRMM)
62. Anti-BCMA CAR T-Cell Commercial Slot Allocation in Patients with Relapsed/Refractory Multiple Myeloma: Insights from a Single Center Experience
63. Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)
64. Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
65. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
66. Oprozomib in patients with newly diagnosed multiple myeloma
67. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
68. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous proteasome inhibitor resistant disease
69. Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy
70. Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes
71. Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
72. Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study
73. Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
74. Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience
75. High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
76. Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
77. Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
78. Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Refractory Multiple Myeloma
79. Heightened Endoplasmic-Reticulum Stress Is a Targetable Vulnerability of Malignant Plasma Cells in Multiple Myeloma
80. A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data
81. Replicative Instability Drives Cancer Progression
82. The Bone Marrow Microenvironment: Novel Targets to Circumvent Minimal Residual Disease and Drug Resistance in Multiple Myeloma
83. Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy
84. Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma
85. P-115: Unc-51 Like Kinase 3 protein (ULK3)-mediated autophagy is responsible for multiple myeloma resistance to chemotherapy
86. Functional transcriptomic landscape informs novel therapeutic strategies in multiple myeloma
87. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma
88. Multiple Myeloma : A Story of Genes and the Environment
89. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
90. CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation
91. Sequence of novel agents in multiple myeloma: An instrumental variable analysis
92. Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma
93. Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting
94. Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel in Multiple Myeloma
95. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
96. Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience
97. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
98. Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab
99. Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
100. Acid Ceramidase (ASAH1) Mediates Intrinsic and Intercellular Transfer of Proteasome Inhibitor Resistance in Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.